Agenda for Day 2 - Wednesday August 12th, 2026 - EST/EDT (Eastern Daylight, GMT-4)
Compliance data problems rarely start in a reporting system. They start in the field at the moment of HCP engagement, when a transfer of value is logged.
In this session, Vanigent shares findings from a live deployment with a pharma field team: what changed when AI guidance was built into the field workflow itself, rather than applied after the fact. Drawing on real pilot outcomes across time savings, compliance accuracy, and audit readiness, the session closes with a live demonstration of the technology running on real field scenarios.
Attendees will see how AI-guided field execution improves:
Data accuracy at the point of engagement
Real-time error detection before anything is submitted
HCP documentation completeness in the field
Audit trail integrity from event to report
Field adoption and satisfaction, because controls only work when people actually use them
When compliance intelligence lives where the work happens, the data quality problem starts shrinking before it ever reaches an audit.
- Goz Alhir - Vice President of Sales, Business Development & Operations, Vanigent
- Dawn DiPierro - Director of Global Compliance Operations, Insmed
- Explore how companies are reevaluating speaker program design to balance educational value, compliance expectations and appropriate utilization
- Gain perspectives on emerging expectations around documentation, rationale and oversight as scrutiny on these programs continue to increase
- Micah Ackerman - Director, Compliance Business Partner, Boehringer Ingelheim
- Erik Gross - Compliance Specialist, Novartis
- This session is meant to be a follow-up to the Modern HCP Engagement Systems session from Day 1, where participants can take a deeper dive, participate in an interactive Q&A focused on real‑world challenges, audience questions, and practical approaches to strengthening HCP engagement operations
- Interact with peers and share what is working and what other companies have done to strengthen their HCP Engagement systems through automation and AI
- Examine system scalability, integration considerations, and emerging enhancements and AI-enabled features
- Dawn DiPierro - Director of Global Compliance Operations, Insmed
- Christian Richardson - Director of Compliance, Celltrion USA
- Examine how teams are rethinking processes, workflows and cross-functional alignment to support timely, accurate and resource-efficient transparency operations
- Review strategies for optimizing approval pathways, strengthening communications with business partners and reducing manual rework
- Explore how different tools and process simplifications can drive consistency while allowing compliance teams to focus on higher-value activities
- Rabail Ali - Product Leader | Transparency Reporting Solution, qordata
- Shane White - Director, Compliance, Integra
- Sulay Desai - Senior Manager, Compliance Operations, ConvaTec
- Explore how compliance teams are beginning to use predictive analytics and machine learning to identify engagement risks earlier and more accurately
- Review practical applications for AI, including anomaly detection, pattern recognition and prioritization of higher-risk activities or documentation gaps
- Discuss considerations for implementation, governance and cross-functional collaboration to ensure AI-driven monitoring supports
- Björn Dupre - Executive Director of Compliance Monitoring & Investigations, Bayer
- Sara Merin - Senior Assistant General Counsel, US Office of Ethics & Compliance, Bayer
- Tim Abbott - Associate Director, Global Compliance Systems and Data Analytics, BeOne Medicines
- Examine the leading sources of data discrepancies, including upstream errors, manual edits and inconsistent documentation that directly impacts aggregate spend reporting
- Review practical methods for improving data checks, reducing manual corrections and ensuring consistent, accurate data flows from all business functions
- Discuss process and governance enhancements that help teams maintain data integrity even during restrictive timelines or high-volume reporting periods
- Caitlin Oroho - Manager, Global Compliance, PTC Therapeutics, Inc.
- Dan LaVallee - Director of Transparency Reporting, Genmab
- Jason DiPietro - Senior Manager, Compliance Data Analytics and Transparency Reporting, Lundbeck US
- Explore how organizations are integrating data privacy and access controls into AI-supported processes, ensuring compliance with internal standards and external regulations
- Review considerations for limiting unnecessary data exposure, controlling who can access sensitive information and ensuring AI tools use data responsibly
- Nereida Parks - Regional AI, HIPAA, Privacy Officer, OCA, Olympus Corporation
- Ericka Watson - Former Chief Privacy Officer, Regeneron
- Examine how companies are navigating FMV challenges across speaking, consulting and advisory engagements as expectations around justification and documentation continue to increase
- Discuss practical approaches to improving rate consistency, strengthening rationale, and supporting audit readiness
- Explore how organizations are enhancing FMV processes to balance risk management with operational efficiency
- Tim Roberts - Former Chief Compliance Officer, Legend Therapeutics
- Rachael Kopeck - Director of Compliance & Ethics, Penumbra
- Explore updated methods for identifying, evaluating and tiering HCPs
- Discuss how organizations use data and analytics to support more objective and consistent tiering decisions
- Hear best practices for creating consistent, scalable tiering frameworks across commercial and medical teams
- Christopher Corallo - Former, Global Chief Compliance Officer, Convatec
- Maria Villanueva - Director, Ethics & Compliance, BioTissue
- Yelena Ferreira - Head of Compliance and Assistant General Counsel, Pharmacosmos Therapeutics
- Explore how senior compliance and transparency leaders evaluate new tools and service providers, including the criteria used to assess risk, value, scalability, and organizational fit
- Examine how initiatives are championed internally, the stakeholders involved in approvals, and the factors that influence whether proposals gain momentum or stall
- Discuss what internal teams and vendors need to demonstrate beyond functionality to build a compelling, leadership‑ready case that secures final sign‑off
- Aisha Ghazi Babar - General Counsel, Chief Compliance Officer & Corporate Secretary, Pierre Fabre
- Karen Lowney - Head of Ethics & Compliance, Sun Pharmaceutical
- Review approaches for monitoring field-based activities, including speaker program execution, HCP interactions and meal distribution practices
- Examine common documentation challenges and how clearer guidance, standardized tools and ongoing training can help field teams stay current with evolving requirements
- Discuss methods for identifying issues earlier, improve escalation pathways and provide real-time feedback to reduce reporting risks
- Jamie Lutz - Associate Director, U.S. Compliance Monitoring, Gilead Sciences
- Björn Dupre - Executive Director of Compliance Monitoring & Investigations, Bayer
- Christian Richardson - Director of Compliance, Celltrion USA
- Learn the best practices for overseeing third-party vendors involved in data collection, HCP identification, system integration and transparency reporting
- Examine approaches for evaluating vendor performance, documenting shared responsibilities and ensuring data accuracy across complex multi-vendor ecosystems
- Discuss strategies for strengthening accountability, improving communication pathways and mitigating operational risks, particularly for small and midsize companies with limited internal resources
- Patrick Thibodeau - Senior Compliance Manager, Kyowa Kirin, Inc.
- Brenda Crabtree - Senior Director of Commercial Legal & Compliance, Kura Oncology
- Review common master data challenges, including duplications, conflicting records and incomplete HCP profiles that complicate downstream reporting
- Explore methods for strengthening HCP identification through validation rules, data cleansing and technology-enabled matching
- Discuss how improved data governance and stronger cross-functional coordination support more accurate, reliable HCP master data management
- Inge Tham - Senior Manager, HCP Transparency Reporting, Edwards Lifesciences
- Jaime Melendez - Enterprise Data and AI Governance, CSL
- Examine how companies are assessing field interactions, meal spend, and speaker utilization to identify low-value engagement patterns
- Explore approaches for improving targeting, reallocating resources more effectively and enhancing both educational and strategic value
- Gain insights into emerging expectations around spend management as financial pressures increase
- Peter Lee - Vice President, Chief Compliance Officer, Kura Oncology
- Examine how organizations are deploying AI and advanced analytics to support compliant, data‑driven HCP engagement strategies
- Assess AI‑enabled capabilities that strengthen data accuracy, automation, and issue identification across transparency and aggregate spend reporting
- Outline governance structures, oversight mechanisms, and control models that enable responsible and defensible AI use in regulated environments
- Karthik Parasa - Chief Technology Officer, Cresen Solutions
- Jacob Wolf - Chief Commercial Officer, Cresen Solutions
- Shane White - Director, Compliance, Integra
- Explore how organizations strengthen issue identification, escalation, and remediation processes to support more proactive and transparent risk management
- Review approaches for developing internal controls, particularly for small and midsize biopharma teams with limited resources and infrastructure
- Eleni Farrell - US Compliance Business Partner, Insmed
- Aisha Ghazi Babar - General Counsel, Chief Compliance Officer & Corporate Secretary, Pierre Fabre
- Examine key patterns and data signals that often precede audit findings, errors, or compliance concerns across transparency and HCP engagement activities
- Explore practical early-warning tools and monitoring approaches that are adaptable for both large organizations and smaller biopharma teams without advanced systems
- Discuss how timely detection, targeted escalation and structured review cycles can strengthen audit readiness and reduce downstream risks
- Poonam Maharjan - Director, Ethics & Compliance, Lantheus
- Examine how mergers, acquisitions, and system consolidations affect data consistency and transparency reporting readiness
- Review strategies for managing integrations finance, commercial operations, medical affairs and IT to reduce disruptions and reporting gaps
- Discuss practical steps for maintaining data integrity during transitions, including validation processes and cross-functional coordination
- Brenda Crabtree - Senior Director of Commercial Legal & Compliance, Kura Oncology
- Patrick Thibodeau - Senior Compliance Manager, Kyowa Kirin, Inc.
- Erik Gross - Compliance Specialist, Novartis
- Explore how Corcept Therapeutics built a high resilience, end to end aggregate spend and HCP engagement data ecosystem designed to withstand organizational changes, new data flows, and evolving transparency requirements
- Hear firsthand how the system captures speaker programs, HCP interactions, contracting data, expenses, touchpoints and real time changes with minimal disruption and exceptionally strong data integrity
- Learn how the team designed future proof workflows that can scale with business growth, absorb process changes and maintain reporting accuracy even during periods of restructuring or evolving operational models
- Ben McKinley - Associate Director, Transparency & Compliance, Corcept Therapeutics Inc
- Explore how companies are applying AI and automation to streamline data processing, reduce manual workload, improve reporting timelines, and identify anomalies earlier in the transparency lifecycle.
- Examine real‑world examples of automated workflows, machine learning models, and anomaly‑detection tools that enhance data quality, strengthen audit readiness, and improve downstream reporting accuracy.
- Discuss governance and oversight considerations, including data privacy safeguards, model transparency, role‑based access, and responsible AI adoption to ensure automated tools support, not replace critical compliance decision‑making
- Charles de Gaspe Beaubien - Founder and Chief Commercial Officer, Groupize
- Vishal Khapane - Senior Director, External Expert Engagement Services, AstraZeneca
- Explore how transparency, HCP engagement, data governance, and monitoring functions are converging and what this means for future organizational structures, ownership models, and cross‑functional collaboration
- Examine emerging expectations from regulators, business partners, and external stakeholders, and how companies are rethinking processes, systems, and decision frameworks to prepare for the next phase of transparency evolution
- Discuss the long‑term capabilities organizations must build, including data literacy, agile workflows, and AI‑ready governance, to stay ahead in an increasingly complex and integrated compliance environment
- Leah Osowski - Director, Transparency Reporting, Americas, Johnson & Johnson
- Tim Abbott - Associate Director, Global Compliance Systems and Data Analytics, BeOne Medicines
- Saron Djeregna - Global Manager - Risk Management, Training, & Transparency, Teleflex
